Table 5. Receiver operating characteristic curve analyses showing the utility of alone or combined markers for differentiating of benign breast disease and breast cancer.

Tumor marker	SEN	FNR	SPE	FPR	PPV	NPV	AUC
CEA (ng/ml)	58	42	72.2	27.8	69	61.6	0.680 (0.631-0.727)
CA15-3 (U/ml)	86.5	13.5	67.4	32.6	73.9	82.4	0.810 (0.768-0.848)
MPV (fL)	76.5	23.5	59.9	40.1	67.1	70.4	0.688 (0.640-0.734)
PDW (%)	94.5	5.5	49.7	50.3	66.8	89.4	0.789 (0.744-0.828)
Fbg (g/l)	48	52	84.5	15.5	76.8	60.3	0.687 (0.638-0.733)
CA15-3+MPV+Fbg	82	18	74.3	25.7	77.4	79.4	0.837 (0.796-0.872)
CA15-3+PDW+Fbg	82.5	17.5	82.9	17.1	83.8	81.6	0.900 (0.866-0.928)

SEN, sensitivity; FNR, false negative rate; SPE, specificity; FPR, false positive rate; PPV, positive predictive value; NPV, negative predictive value; AUC, area under curve; CEA, carcinoembryonic antigen; CA15-3, cancer antigen 15-3; MPV, mean platelet volume; PDW, platelet distribution width; Fbg, fibrinogen. The cutoff values of CEA, CA15-3, fibrinogen, MPV and PDW were 1.17 ng/ml, 5.77 U/ml, 2.79 g/l, 9.6 fL, and 15.7 %, respectively.